A new response in a third indication has been observed in the fifth and final dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody); no dose-limiting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback